CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Dec 2024
- Ended
- Sept 2025
- Type of study
- Interventional
- Treatments tested
- CPI 613
- Metformin
- Blood draws
- Bone marrow biopsy
- Record updated
- 19 September 2024
- Why it stopped
- PI decided not to move forward with the study
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Patients must have histologically or cytologically documented relapsed and/or refractory Acute Myeloid Leukemia or granulocytic sarcoma
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 3
- Must be ≥ 18 years of age
- Persons of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation
- Persons who are having sexual relationships in which their partner may become pregnant must practice effective contraceptive methods during the study treatment and for 60 days after the last dose of study treatment, unless documentation of infertility exists
- Mentally competent, ability to understand and willingness to sign the informed consent form
- Patients with persisting, non-hematologic, non-infectious toxicities from prior treatment must be ≤ Grade 2 and must be documented as such
- Laboratory values ≤ 2 weeks prior to the start of study treatment must be the following:
- Aspartate aminotransferase [AST/SGOT] ≤ 5x upper normal limit [UNL],
- Alanine aminotransferase [ALT/SGPT] ≤ 5x UNL
- Bilirubin ≤ 3x UNL
- Albumin ≥ 2.0 g/dL or ≥ 20 g/L
- Serum creatinine ≤ 2.0 mg/dL
- Presence of central venous catheter or willing to have central venous access placed
Who cannot take part
- Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 1 week prior to initiation of CPI-613 treatment with the following exceptions:
- The use of Hydrea or any targeted oral agent is allowed up to the day before initiation of treatment
- Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patient
- Patients with active central nervous system (CNS) or epidural tumor
- Pregnant persons, or persons of child-bearing potential not using reliable means of contraception (because the teratogenic potential of CPI-613 is unknown)
- Breastfeeding individuals because the potential of excretion of CPI-613 into breast milk. (Note: Breastfeeding individuals are excluded because the effects of CPI-613 on a nursing child are unknown)
- Unwilling or unable to follow protocol requirements
About the trial
What the trial wants to find out
The purpose of this research study is to find out what effects (the good and bad) the combination treatment of metformin and CPI-613 has in treating participants with acute myeloid leukemia or granulocytic sarcoma that has either returned after treatment or did not respond to treatment.
The group in the trial
- Treatment - CPI-613 with MetforminTreatment being tested
Induction therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) for two cycles of treatment. Maintenance therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) until progression, intolerable toxicity of withdrawal of consent.
Treatment: CPI 613, Metformin, Blood draws, and Bone marrow biopsy
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open Label, Pilot Phase II Study to Evaluate the Feasibility and Efficacy of CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Record updated
- 19 September 2024